摘要
目的:观察诺和锐30和诺和灵30R治疗老年2型糖尿病的临床效果。方法:将2009年1月—2011年1月期间住院的年龄≥60岁的2型糖尿病患者120例随机分为诺和锐30组(60例)、诺和灵30R组(60例),均为每日早晚2次皮下注射。治疗12周,观察两组血糖控制等临床效果,并分析比较。结果:两组的7点血糖、糖化血红蛋白(HbA 1c)较治疗前明显下降,差异有统计学意义(P<0.05)。治疗后诺和锐30组早餐后2 h、晚餐后2 h、睡前22:00血糖较诺和灵30R组低,差异有统计学意义(P<0.05);两组空腹、午餐前、晚餐前血糖、午餐后2 h及HbA 1c变化差异无统计学意义(P>0.05)。诺和锐30组低血糖发生率低于诺和灵30R组(P<0.05)。诺和锐30组日胰岛素用量少于诺和灵30R组(P<0.05)。两组患者体重的增加值差异无统计学意义(P>0.05)。结论:治疗后诺和锐30组的早、晚餐后及睡前22:00血糖有明显降低,低血糖发生率较低,更适宜以餐后血糖高为主的老年2型糖尿病患者。
Objective：To observe the curative effect of novorapid 30（BIAsp 30） and novolin 30（BHI 30） in elderly patients with type 2 diabetes.Methods：Hospitalized elderly patients from January 2009 to January 2011 were randomly divided into the BIAsp 30 group（60 patients） and the BHI 30 group（60 patients）.The tow groups were treated with BIAsp 30 or BHI 30 twice daily in morning and evening.Through 12 weeks′ treatment,plasma glucose control and the other incidence were compared in two groups.Results：The seven-times blood glucose and glycosylated hemoglobin（HbA1c） decreased distinctly in two groups after treatment（P0.05）.In the BIAsp 30 group,2 hours postprandial glucose levels after breakfast and supper,22：00 level were significantly decreased（P0.05）.the other four times glucose levels and HbA1c were not different significantly between the tow treatments（P0.05）.The rate of hypoglycaemia in the BIAsp 30 group was much lower than that in the BHI 30 group（P0.05）.The quantity of daily insulin in the BIAsp 30 group was significantly less than that in the BHI 30 group（P0.05）.The body weight of the two groups had no distinct difference（P0.05）.Conclusion：After treatment,in the BIAsp 30 group,2 hours postprandial glucose levels after breakfast and supper,22：00 level were significantly decreased.The rate of hypoglycaemia in the BIAsp 30 group was much lower than that in the BHI 30 group.BIAsp 30 is more suitable in elderly patients with type 2 diabetes,especially in patients with high postprandial blood glucose.
出处
《临床医药实践》
2012年第4期256-258,共3页
Proceeding of Clinical Medicine
